Edition:
United States

Novogen Ltd (NVGN.OQ)

NVGN.OQ on NASDAQ Stock Exchange Capital Market

1.72USD
24 Feb 2017
Change (% chg)

$0.02 (+1.18%)
Prev Close
$1.70
Open
$1.68
Day's High
$1.89
Day's Low
$1.68
Volume
12,046
Avg. Vol
5,325
52-wk High
$2.83
52-wk Low
$1.39

NVGN.OQ

Chart for NVGN.OQ

About

Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug... (more)

Overall

Beta: 0.24
Market Cap(Mil.): $30.94
Shares Outstanding(Mil.): 19.33
Dividend: --
Yield (%): --

Financials

  NVGN.OQ Industry Sector
P/E (TTM): -- 44.59 29.71
EPS (TTM): -0.54 -- --
ROI: -30.87 -3.18 12.94
ROE: -30.70 5.86 14.09

BRIEF-Novogen awarded grant for novel drug discovery

* Novogen awarded grant of up to $3mln for novel drug discovery Source text for Eikon: Further company coverage:

Feb 08 2017

BRIEF-Novogen entered into worldwide licensing agreement with Genentech

* Entered into worldwide licensing agreement with Genentech Source text for Eikon: Further company coverage:

Oct 30 2016

BRIEF-Novogen acquires Glioblast for A$2.1 million

* Glioblast Pty Ltd, a privately-held neuro-oncology company based in Sydney, Australia, will be acquired for AU$ 2.1 million

Oct 30 2016

More From Around the Web

Earnings vs. Estimates